Eli Lilly and Company (NYSE:LLY) is considered one of the best stocks for a 20-year long-term stock portfolio, despite a YTD decline of over 5%. On August 8, shares dropped to $625-$626 but have since increased by nearly 17% due to improved investor sentiment. HSBC analyst Rajesh Kumar upgraded Eli Lilly to Hold from Sell with a price target of $700, citing progress on the company’s oral weight-loss drug.

The trial for Eli Lilly’s oral weight-loss drug showed significant weight loss in patients with obesity and type 2 diabetes, outperforming expectations and a rival’s treatment. FDA approval is expected in 2026, with forecasts predicting $15.5 billion in annual sales by 2032. Most analysts now have a Buy rating on Eli Lilly with a consensus 1-year median price target of $900, indicating a 23% potential upside. Eli Lilly focuses on diabetes, oncology, immunology, and neuroscience medicines.

Read more at Yahoo Finance: HSBC Upgrades Eli Lilly (LLY) to Hold, Lifts Price Target to $700